Enzyme potentiated desensitization (EPD) is done to ease symptoms of allergies and asthma. It injects a low dose of compounds into the skin. This aims to lower the body’s reaction to things that cause symptoms.
The Food and Drug Administration does not allow EPD to be imported into the United States.
Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.
Talk to your doctor about any supplements or therapy you would like to use. Some can interfere with treatment or make conditions worse.
Treatment Outcomes
A1. Galli E, Bassi MS, et al. A double-blind randomized placebo-controlled trial with short term beta-glucuronidase therapy in children with chronic rhinoconjuctivitis and/or asthma due to dust mite allergy. J Investig Allergol Clin Immunol. 2006;16(6):345-350.
A2. Radcliffe MJ, Lewith GT, et al. Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study. BMJ. 2003 Aug 2;327(7409):251-254.
A3. Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). Ann N Y Acad Sci. 2001 Jun;931:310-341.
Last reviewed October 2019 by EBSCO NAT Review Board
Eric Hurwitz, DC
Last Updated: 5/29/2020